GIST patient registry to improve real-world care
Part of Cancer, Digestive system clinical trials.
This observational study keeps a registry of people diagnosed with gastrointestinal stromal tumor (GIST) to collect real-life information over time. It may help doctors better understand outcomes and care patterns for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with gastrointestinal stromal tumor (GIST)
- You are at least 20 years old
- Your GIST diagnosis was confirmed by tissue testing (biopsy/surgery) between Jan 1, 2010 and Dec 31, 2020
- You agree to sign the informed consent form if the study requires it at your site
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
This study looks at how safe laparoscopic surgery is for stomach GISTs that are 5 cm or larger. If you’re eligible and choose to participate, your team will plan and perform surgery and track safety outcomes.
This trial tests whether adding radiation therapy to the drug ripretinib can help people with advanced gastrointestinal stromal tumors (GIST) that can't be removed by surgery and have stopped responding to other treatments. It aims to see if this combination is safe and effective.
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
This study is creating a registry to track people with GIST over time. Participating helps researchers learn more about the disease and improve future care.
Hear when a new Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.